Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for BYDUREON PEN
- Exenatide for Smoking Cessation and Prevention of Weight Gain
- Exenatide for Treating Cocaine Use Disorder
- Brain Activation and Satiety in Children 2
- Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
- Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
- Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.
- Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
- Effects of Exenatide on Motor Function and the Brain
- Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
- Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
- Exenatide Once Weekly for Smoking Cessation
- Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins
- An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
- Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment
- GLP-1/Basal Insulin Combination Therapy
- Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients
- Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
- Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
- Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects
- Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity
- Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
- Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
- Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
- Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
- Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
- Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus
- Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
- Trial of Exenatide for Parkinson's Disease
- A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
- Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
- Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
- Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
- Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
- Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
- A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
- Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
- Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
Clinical trials list
click for details